March 2026 in “Journal of the American Academy of Dermatology” In this study, patients with active lymphocytic cicatricial alopecia showed significant improvement using a three-stage treatment regimen involving Tofacitinib, Apremilast, and Crisaborole, with 93.5% experiencing marked improvement and only three mild adverse events reported.
December 2018 in “International journal of women’s dermatology” Early diagnosis and strong corticosteroids are crucial for managing lymphocytic cicatricial alopecia.
April 2024 in “Skin health and disease” In this pilot study, participants with lymphocytic primary cicatricial alopecia who applied 6% topical gabapentin solution twice daily for 12 weeks experienced significant symptom reduction, though there was no noticeable change in nerve fibre density or neuropeptide expression.
1 citations
,
March 2025 in “Journal of Investigative Dermatology” Metabolic issues may trigger lymphocytic cicatricial alopecia, and treatments targeting these issues could help.
May 2026 in “JAAD International” This article notes the lack of US prevalence data for primary lymphocytic cicatricial alopecias due to the recent introduction of subtype-specific ICD-10 codes and highlights the importance of early diagnosis for hair preservation.